Lumito AB (publ) has carried out a directed unit issue to professional and private investors through an accelerated book-building process. The unit issue provides Lumito with a capital injection of approximately SEK 45 million before transaction costs.
To enable existing Lumito shareholders to be compensated to some extent for the dilution effect of the issue, Lumito’s Board of Directors also took the decision to issue additional warrants for allocation to existing shareholders free of charge.
Full exercise of all issued warrants could raise up to approximately SEK 72.4 million for Lumito.
Lumito specialises in imaging technology in the medical R&D sector. Lumito’s patented technology uses nanoparticle markers to create high-resolution images of tissue in tumours, for example. The technology has a range of potential applications, but Lumito has chosen to focus primarily on digital pathology.
Lindahl Law Firm assisted Lumito as legal adviser in the capital raising programme. Lindahl’s team consisted of Johan Herrström and Pontus Söderberg.
